PropThink: FDA Interested in Accelerating Contrave’s Approval; Timeline Not Yet Clear

[ACN Newswire] – By Jake KingThe competition among obesity-drug makers continues to heat up Monday following an announcement from OrexigenTherapeutics (NASDAQ:OREX) that the company may be able to expedite the approval … more

View todays social media effects on ARNA

View the latest stocks trending across Twitter. Click to view dashboard